SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising...

Full description

Saved in:
Bibliographic Details
Main Authors KOSEMUND, Dirk, STÖCKIGT, Detlef, OFFRINGA, Rienk, WERBECK, Nicolas, WORTMANN, Lars, NGUYEN, Thi, Thanh, Uyen, HERBERT, Simon, Anthony, BÖMER, Ulf, LECHNER, Christian, KOBER, Christina, PETERSEN, Kirstin, SCHMEES, Norbert, MEIER, Robin, Michael, KERSCHGENS, Isabel, Patrizia, GREES, Mareike, KIRCHHOFF, Dennis
Format Patent
LanguageEnglish
Spanish
Published 03.10.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients. La presente invención se refiere a compuestos de aminoquinolona de la fórmula general (I) donde R1, R2, R3, R4, R5, R6, R7, R8 y n han sido definidos en la memoria, métodos de preparación de dichos compuestos, compuestos intermedios de utilidad para preparar dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento y/o profilaxis de enfermedades, en particular de trastornos regulados por diacilglicerol quinasa alfa, como agente único o en combinación con otros principios activos.
Bibliography:Application Number: CR20220236